Internship

2025 Co-Op

INT Manufacturing

Posted on 10/16/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Norwood, MA, USA

Spring Co-Op opportunity in Norwood, MA from January 21, 2025 – June 20, 2025. Applicants must be available for the entire duration of the Co-Op.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Current student enrolled in a Bachelors or Master’s program in Chemical Engineering, Biochemical Engineering, Bioengineering, Biomolecular Engineering, Chemistry, Biochemistry, Biomedical Engineering, Biophysics, Biostatistics, Biotechnology, Mathematics, Molecular Biology, Pharmaceutical Science, Statistics, or a related field
  • Strong fundamental scientific and engineering skills for the evaluation of experimental data
  • Laboratory skills applicable to bioprocess development and analytical methods
Responsibilities
  • Participate in cross-functional troubleshooting and suggest operational improvements in manufacturing settings under supervision.
  • Assist in supporting technology transfer projects, including helping coordinate process information exchange, documenting process parameters, and tracking process performance.
  • Take ownership of specific manufacturing-related projects, including planning, executing, and tracking progress to meet project milestones and deadlines.
  • Contribute to the resolution of technical deviations and process improvements with data-driven root cause analyses, CAPAs, and change controls under the guidance of more senior engineers.
  • Participate in the analysis of manufacturing performance through data review and help maintain data repositories.
  • Follow all relevant GxP regulations, guidelines, and company policies to ensure compliance with regulatory and internal requirements.
  • Execute tasks precisely as defined in internal guiding documents including but not limited to standard operating procedures (SOPs) and work instructions.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in the process of protein synthesis in cells. Their approach involves creating mRNA-based therapies that instruct cells to produce proteins that can help treat diseases. This method allows for a more flexible and efficient way to develop and manufacture medicines compared to traditional methods. What sets Moderna apart from its competitors is its exclusive focus on mRNA technology, which has the potential to create a new category of treatments. The company's goal is to harness the power of mRNA to significantly improve patient outcomes and transform the landscape of medicine.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's Melbourne facility accelerates vaccine production by bypassing regulatory hurdles.
  • Collaboration with OpenAI enhances drug discovery efficiency using AI.
  • Participation in major investor conferences attracts new investors and partnerships.

What critics are saying

  • Potential removal from Nasdaq 100 could affect investor perception and stock liquidity.
  • Bypassing safety steps in Australia may raise regulatory and public safety concerns.
  • Hong Kong's reluctance to vaccinate indicates challenges in market acceptance.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious diseases, immuno-oncology, and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE